Radiation oncology firm Nucletron credited a renewed focus on brachytherapy treatment and an expanding product line in external-beam treatment planning software for sales growth in 2008.
Net sales totaled 112.4 million euros ($165 million U.S.) last year, surpassing the Veenendaal, Netherlands, company's projections. The company did not provide net income or prior-year financial results because it is privately held.
In 2008, Nucletron introduced its Oncentra Brachy volume-based treatment planning product, designed to optimize cancer treatment planning with brachytherapy. The firm's Oncentra RT Viewer also was approved last year by the U.S. Food and Drug Administration (FDA).
CEO Jos Lamers said that thus far Nucletron is on track to achieve its 2009 goals.
Related Reading
Nucletron to partner with ART on AccuBoost, February 13, 2009
Nucletron receives FDA clearance for RT viewer, November 21, 2008
Nucletron receives Canadian clearance, November 13, 2008
Nucletron debuts gynecology brachytherapy, September 9, 2008
Nucletron taps new CEO, June 30, 2008
Copyright © 2009 AuntMinnie.com
